本帖最后由 老马 于 2012-1-13 21:20 编辑
$ z6 T% ]/ T" [: X( A; `
% N2 F u( l) M- H8 ]爱必妥和阿瓦斯丁的比较. P: D; v" U3 O7 S) _
8 E1 q$ k& c3 n! ]! A1 U+ q' h" xhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/* n: J4 u1 l7 K L: |3 q. s, a4 q
8 f+ N' J p8 U8 Z4 a
# B2 H- U$ S4 n
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, `' U. [+ V; H2 _7 `6 U
==================================================
/ N" z% F* Z! m; n& b" y# VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)3 K, {7 L; O7 h9 k+ }% Q! G3 j R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* d4 q- U# s2 R, z+ V! S) h$ B1 h, |Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: c2 V/ |! |# ~5 N# [/ n
|
显身卡
4 i9 H A! R' K8 n
